[Study on Material Base of Panax ginseng for Treating Brain Ischemia Based on Molecular Docking].

中药材 Pub Date : 2016-06-01
Gui-zhu Deng, Chun-wei Wu, Jie-xin Lin, Chao Cheng, Shu-mei Wang
{"title":"[Study on Material Base of Panax ginseng for Treating Brain Ischemia Based on Molecular Docking].","authors":"Gui-zhu Deng,&nbsp;Chun-wei Wu,&nbsp;Jie-xin Lin,&nbsp;Chao Cheng,&nbsp;Shu-mei Wang","doi":"","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>On the basis of molecular docking,to study the mechanism of Panax ginseng in the treatment of ischemic stroke.</p><p><strong>Methods: </strong>The small molecules of Panax ginseng based on molecular docking technology docked with 20 key targets protein of cerebral ischemia, and multi-component protein target network was established by Cytoscape 3. 1. 1 software. At the same time,the two active molecules of the Panax ginseng of Rb2 and 20( R)-ginsenoside Rg2 were also analyzed by VEGF and Caspase-3,which were the key protein in brain ischemia.</p><p><strong>Results: </strong>There were 31 active molecules of Panax ginseng combined strongly with five or more than five protein targets after molecular docking, and only four active molecules of Panax ginseng combined strongly with ten or more than ten protein targets. The two active molecules of Rb2 and 20( R)-ginsenoside Rg2 in the Panax ginseng had a very strong combination with VEGF and Caspase-3,respectively,and the docking scores were more than 7. 0.</p><p><strong>Conclusion: </strong>Molecular docking technology screening active substances of Panax ginseng plays a practical significance in the treatment of ischemic stroke, which offers the foundation to study the chemical constituents of composite prescription.</p>","PeriodicalId":15312,"journal":{"name":"中药材","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2016-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"中药材","FirstCategoryId":"3","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Objective: On the basis of molecular docking,to study the mechanism of Panax ginseng in the treatment of ischemic stroke.

Methods: The small molecules of Panax ginseng based on molecular docking technology docked with 20 key targets protein of cerebral ischemia, and multi-component protein target network was established by Cytoscape 3. 1. 1 software. At the same time,the two active molecules of the Panax ginseng of Rb2 and 20( R)-ginsenoside Rg2 were also analyzed by VEGF and Caspase-3,which were the key protein in brain ischemia.

Results: There were 31 active molecules of Panax ginseng combined strongly with five or more than five protein targets after molecular docking, and only four active molecules of Panax ginseng combined strongly with ten or more than ten protein targets. The two active molecules of Rb2 and 20( R)-ginsenoside Rg2 in the Panax ginseng had a very strong combination with VEGF and Caspase-3,respectively,and the docking scores were more than 7. 0.

Conclusion: Molecular docking technology screening active substances of Panax ginseng plays a practical significance in the treatment of ischemic stroke, which offers the foundation to study the chemical constituents of composite prescription.

分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
[基于分子对接的人参治疗脑缺血物质基础研究]。
目的:在分子对接的基础上,研究人参治疗缺血性脑卒中的作用机制。方法:基于分子对接技术,将人参小分子与20个脑缺血关键靶蛋白对接,利用Cytoscape 3构建多组分蛋白靶网络。1. 1软件。同时用VEGF和脑缺血关键蛋白Caspase-3对人参中的两种活性分子Rb2和20(R)-人参皂苷Rg2进行分析。结果:分子对接后,人参有31个活性分子与5个或5个以上蛋白靶点强结合,只有4个活性分子与10个或10个以上蛋白靶点强结合。人参中的两种活性分子Rb2和20(R)-人参皂苷Rg2分别与VEGF和Caspase-3有很强的结合,对接评分均在7分以上。0.结论:分子对接技术筛选人参活性物质对缺血性脑卒中的治疗具有现实意义,为复方方剂化学成分的研究提供了基础。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
11364
期刊介绍: "Chinese Materia Medica" magazine was founded in 1978. It is a national-level academic journal of Chinese medicine science and technology approved by the State Science and Technology Commission and the Press and Publication Administration for public distribution at home and abroad. It is sponsored by the Chinese Materia Medica Information Center of the State Food and Drug Administration and is publicly distributed at home and abroad. It mainly reports on new technologies, new methods and new achievements in the production, scientific research and business management of Chinese medicine, and serves to promote the production and scientific and technological development of Chinese medicine, improve the output and quality of Chinese medicine, improve business management, and prosper the Chinese medicine industry.
期刊最新文献
[Contents and the Correlations of the Total Anthocyanins and Saponins of the Vegetative Organs of Panax notoginseng with Purple and Green Aerial Stems at Different Growth Stages]. [Effect of Different Locations and Genotypes on Yield and Accumulation of Bioactive Constituents in Salvia miltiorrhiza]. [Cultivation and Standardized Technology Research on A New Astragalus Variety of Longqi 4]. [Correlation of Agronomic Character of Panax notoginseng in Guangxi with Soil Physical and Chemical Properties]. [Identification of Original Species of Fish Maw by DNA Barcoding].
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1